MDAI — Spectral AI, Inc.

Summary of MDAI Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $3.8 million, down from $7.6 million in Q4 2024, reflecting reduced research direct labor and clinical trial costs.
• Gross Margin: 39.8%, compared to 44.0% in Q4 2024, primarily due to a lower percentage of reimbursed direct labor.
• General and Administrative Expenses: Decreased to $4.0 million from $4.5 million year-over-year.
• Net Income: $0.6 million ($0.02 per diluted share), a significant improvement from a net loss of $7.7 million ($-0.41 per diluted share) in Q4 2024.
• Full Year 2025 Revenue: $19.7 million, down from $29.6 million in 2024.
• Full Year Net Loss: $7.6 million ($-0.29 per diluted share), improved from a net loss of $15.3 million ($-0.85 per diluted share) in 2024.
• Cash Position: Increased to $15.4 million from $5.2 million at the end of 2024.

2. Strategic Updates and Business Highlights

• DeepView System: Progress made towards commercialization, with a focus on the burn indication. The system aims to assist in triaging burn patients, particularly in mass casualty situations.
• FDA Submission: Submitted a de novo application in June 2025; maintaining dialogue with the FDA and hopeful for a response by the end of Q2 2026.
• BARDA Partnership: Received $31.7 million in funding to accelerate DeepView development, building on a long-term relationship with BARDA.
• International Expansion: Positive feedback from the UK market, with plans to update UKCA authorization in 2026 following FDA approval.

3. Forward Guidance and Outlook

• 2026 Revenue Forecast: Approximately $18.5 million, excluding significant contributions from DeepView system sales.
• Commercialization Plans: Preparing for a transition to a commercial organization, including hiring a Chief Commercial Officer and expanding the sales team.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Notable decrease in both Q4 and full-year revenue compared to previous years, attributed to the completion of certain phases of the BARDA contract.
• Dependence on FDA Approval: Future revenue is contingent on FDA approval of the DeepView system, which poses a risk if delays occur.
• Market Adoption Uncertainty: The revenue model post-approval is uncertain, as it depends on how health systems choose to treat the device (purchase vs. lease).

5. Notable Q&A Insights

• Commercialization Readiness: CEO Vincent Capone discussed preparations for commercialization, including hiring a Chief Commercial Officer and engaging consultants for strategic planning.
• BARDA Funding Utilization: The additional BARDA funding will accelerate development and enable earlier manufacturing and deployment of devices post-FDA approval.
• Training and Support: Plans to expand the training force to ensure effective implementation of the DeepView system in burn centers.
• International Opportunities: Potential for revenue generation outside the U.S. as they plan to expand their market presence in the UK, Australia, and GCC nations.

Overall, while Spectral AI demonstrated significant financial improvements and strategic advancements in 2025, the company faces challenges related to revenue generation and reliance on regulatory approvals that could impact future growth.